1662 results for "LSD"
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.
The lancet. Psychiatry – January 01, 2025
Summary
Psychedelic therapy is gaining momentum in mental health treatment, but how therapists work with patients during these sessions varies widely. A comprehensive analysis of 45 studies revealed significant inconsistencies in how psychological support is provided alongside substances like psilocybin, MDMA, and LSD. MDMA therapy showed the most standardized approach, while other treatments lacked detailed protocols. Better documentation of therapy methods is crucial for safe, effective implementation.
Abstract
Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic com...
Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use
Journal of Psychoactive Drugs – November 06, 2024
Summary
Exclusive psychedelic microdosers, a subset of 2488 individuals from a survey of 6193 consumers, exhibit distinct demographics and substance use patterns. They are older (46.4 vs. 42.0 years), predominantly female (68.4% vs. 44.7%), and report less non-psychedelic substance use (3.8 vs. 4.7 substances) compared to those also using macrodoses. Most microdose multiple times monthly, often with psilocybin (74.5%) or LSD (34.4%), primarily for wellbeing (73.0%), though 64.6% don't test their substances.
Abstract
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described t...
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Journal of Psychoactive Drugs – November 06, 2024
Summary
A critical review of nine **psychedelics and drug studies** reveals a significant challenge for **medicine**: nearly 78% had poor **masking** success. This means participants often knew if they received the active **chemical compounds**—like psilocybin or LSD, often from **chemical synthesis**, or natural **alkaloids**—or a **placebo**. This complicates attributing positive changes in **psychology** to the drug alone. For instance, 60-75% of **placebo** groups in **clinical psychology** still showed large effect sizes. **Psychotherapists** must consider these unmasking influences.
Abstract
Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. Howe...
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
BMC Medical Education – October 24, 2024
Summary
Australia has already approved MDMA and psilocybin for mental health, highlighting Europe's urgent need to advance medical education in psychedelic-assisted therapy. With USA trials in Phase III, Germany is poised to lead Europe in developing robust frameworks for integrating innovative Psychedelics and Drug Studies into Medicine. This includes defining ethical Psychotherapy Techniques and Applications, practitioner training, and regulatory oversight. Such infrastructure development aims to ensure proficient care, potentially reclaiming Europe's historical lead in Psychology and psychiatric innovation, as seen with Switzerland's 2014 reintroduction of MDMA and LSD for restricted medical use.
Abstract
As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psyche...
Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022).
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
Despite widespread use of psychedelics, only 28 drug-related deaths were linked to these substances across England, Wales, and Northern Ireland over 25 years. While each death is tragic, this remarkably low number supports psychedelics' relative safety profile. Most cases involved multiple substances, with LSD and psilocybin being most common. Adverse effects were typically connected to unsafe physical environments or toxicity from mixing drugs.
Abstract
Psychedelic drugs are increasingly visible in society once more, but their risks and adverse effects have received less attention than perhaps they...
Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task
Scientific Reports – October 18, 2024
Summary
Classic psychedelic compounds, including synthesized alkaloids like LSD and naturally occurring psilocybin, significantly boost emotional empathy. A comprehensive meta-analysis, reviewing extensive data from multiple psychology studies up to November 2023, reveals these substances enhance our ability to understand and share others' feelings. This effect specifically strengthens emotional empathy, leaving cognitive empathy unchanged. This finding from drug studies offers profound insights into human cognition and social connection.
Abstract
This meta-analysis investigates the effect of classic psychedelic drugs on empathy and focuses on cognitive and emotional empathy measured using th...
Exploring the regulatory framework of psychedelics in the US & Europe.
Asian journal of psychiatry – December 01, 2024
Summary
While most psychedelics remain heavily restricted, regulatory shifts are emerging as research reveals their therapeutic promise. The US and EU are developing frameworks to evaluate substances like psilocybin, LSD, and MDMA for mental health treatment. Ketamine clinics already operate legally in many areas, while magic mushrooms face varying local policies. New laws aim to balance patient access with safety controls.
Abstract
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic...
Tags
CCNP Innovations in Neuropsychopharmacology Award
Journal of Psychiatry and Neuroscience – September 19, 2024
Summary
Psychedelics are profoundly reshaping mental health treatment, offering a novel psychiatric framework. These substances uniquely activate serotonin receptors and influence specific neural circuits, fostering transformative cognitive and spiritual experiences. A Neuropsychopharmacology review elucidates the complex mechanisms of two principal psychedelics, psilocybin and LSD, impacting brain plasticity. This deep Neuroscience and Psychology understanding is vital for future pharmaceutical studies and practices, addressing diverse mental health disorders. Such insights could even extend to conditions like Attention Deficit Hyperactivity Disorder, integrating brain, mind, and spirituality.
Abstract
For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last ...
New frontiers in the biosynthesis of psychoactive specialized metabolites
Current Opinion in Plant Biology – September 16, 2024
Summary
The relaxation of psychedelic drug regulations has spurred interest in compounds like Psilocybin and Lysergic acid diethylamide (LSD) for mental health. A review in Drug Studies highlights the intricate biochemistry and biology of hallucinogen production. It details metabolic pathways from diverse plant and fungal interactions, as well as animal sources, yielding five key compounds, including Mescaline, Lysergic acid, and tryptamine derivatives. This exploration of chemical synthesis and alkaloids aims to leverage synthetic biology to create novel psychedelics with superior pharmacology, complementing traditional methods.
Abstract
The recent relaxation of psychedelic drug regulations has prompted extensive clinical investigation into their potential use to treat diverse menta...
Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment.
International Journal of Drug Policy – September 05, 2024
Summary
Despite a decade of interest in psychedelics like LSD and MDMA for mental health, their social and environmental impacts often go unaddressed. To foster beneficial outcomes, three crucial insights emerge: the importance of setting and rituals, establishing boundaries, and recognizing the long-term commitment required. Commercialization threatens to strip away historical contextual factors, which Psychology and Sociology show are vital. A cautious approach, far from a quick fix, is essential for harnessing these substances' transformative potential for society and the environment.
Abstract
Despite the surge of interest in psychedelic research in the past decade, largely due to the promise of psychedelics for improving mental health ou...
Jung, the Rebirth Motif and Psychedelics I: Documenting Jung's Contact with the British Pioneers.
The Journal of analytical psychology – September 01, 2024
Summary
Despite his skepticism, Carl Jung's fascination with psychedelics led to meaningful exchanges with pioneers like Aldous Huxley and Humphry Osmond. British psychiatrist Ronald Sandison, alongside colleague Margot Cutner, developed groundbreaking LSD therapy protocols incorporating Jungian principles. Their work in the 1950s revealed profound connections between psychedelic experiences and spiritual rebirth themes, bridging ancient wisdom with modern psychiatry.
Abstract
C. G. Jung wrote very little about psychedelic drugs and he took a sceptical view of them. However, he was sufficiently impressed by Aldous Huxley'...
Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.
Current topics in behavioral neurosciences – July 31, 2024
Summary
While generally safer than many recreational substances, psychedelics like LSD and psilocybin can profoundly alter consciousness through unique interactions with brain serotonin systems. Their classification includes three main types: phenethylamines, tryptamines, and ergolines. Though showing promise in mental health treatment, these substances carry risks of anxiety, dissociation, and psychological harm, particularly when combined with other drugs or used improperly.
Abstract
Psychedelics are a group of substances within the heterogeneous class of hallucinogenic drugs. Via binding to the serotonin (5-HT) 2A receptor, psy...
Toxicology and Pharmacological Interactions of Classic Psychedelics.
Current topics in behavioral neurosciences – July 24, 2024
Summary
Classic psychedelics like LSD and psilocybin show remarkably low physical toxicity, even at high doses. Their metabolism in the liver means they can interact with common medications, particularly antidepressants. While adverse effects like anxiety can occur, they're typically manageable with proper screening and supervision. Understanding these interactions helps ensure safe therapeutic use.
Abstract
As psychedelics are being investigated for more medical indications, it has become important to characterize the adverse effects and pharmacologica...
The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
The International journal on drug policy – August 01, 2024
Summary
A groundbreaking international survey reveals that personal growth, not recreation, is the primary motivation for psychedelic use across global regions. This comparative analysis of 6,379 adults from 85 countries found that psilocybin, LSD, and MDMA are the most commonly used substances. Usage patterns vary by region, with North Americans more likely to microdose and seek therapeutic benefits. Most users prefer legal, quality-controlled sources and practice infrequent, intentional use.
Abstract
Despite advancements in policies governing psychedelic substances globally, our understanding of real-world psychedelic use and its variations acro...
Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review
Frontiers in Psychiatry – May 14, 2024
Summary
Profound subjective experiences from psychedelics like psilocybin and LSD are directly linked to specific changes in brain functional connectivity. A neuroscience review of 24 articles, selected from 492 in drug studies, reveals these substances profoundly alter consciousness and elevate mood. Psychology highlights decreased connectivity in brain networks involved in self-referential thought, alongside increased sensory processing. Such neurophysiological shifts offer a potential neural mechanism for reported mystical experiences, informing medicine's exploration of these compounds' therapeutic applications.
Abstract
Intense interest surrounds current research on psychedelics, particularly regarding their potential in treating mental health disorders. Various st...
Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – August 01, 2024
Summary
The eye's retina may be the starting point for visual hallucinations, not just the brain as previously thought. Psychedelics like LSD affect specialized retinal cells called amacrine cells, disrupting normal visual perception before information even reaches the brain. This insight comes from studying both psychedelic experiences and rare conditions affecting the visual pathway, revealing how alterations in retinal processing can trigger vivid hallucinations.
Abstract
Psychedelics like LSD (Lysergic acid diethylamide) and psilocybin are known to modulate perceptual modalities due to the activation of mostly serot...
Effects of hallucinogenic drugs on the human heart
Frontiers in Pharmacology – February 02, 2024
Summary
Beyond their known central nervous system effects, hallucinogens like Lysergic acid diethylamide (LSD) and Psilocybin also profoundly impact heart function. Pharmacology reveals these psychedelics, often products of intricate chemical synthesis and alkaloids, stimulate serotonin receptors, influencing heart rate (chronotropic action) and contraction strength. This includes substances such as Ergotamine and other Lysergic acid derivatives. Understanding this complex chemistry is vital for medicine and drug studies, highlighting a significant neurotransmitter receptor influence on behavior and physiology.
Abstract
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation ...
PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patients.
Pilot and feasibility studies – February 12, 2024
Summary
New research explores an innovative approach to easing end-of-life distress in advanced cancer patients by combining meaning-centered psychotherapy with low-dose psychedelics. The protocol examines whether microdosing lysergic acid diethylamide (LSD) alongside therapy can help reduce anxiety and depression. This groundbreaking New Zealand study includes both indigenous and non-indigenous participants, marking a culturally inclusive approach to mental health care.
Abstract
An advanced cancer diagnosis can be associated with a significant profile of distress. Psychedelic compounds have shown clinically significant effe...
Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways
Ageing Research Reviews – February 01, 2024
Summary
A compelling finding in Neuroscience reveals psychedelics like Psilocybin, DMT, and LSD hold significant promise for treating Alzheimer's disease, a devastating form of dementia. These powerful chemical compounds, with a rich historical context, modulate neurotransmitter receptors to enhance neural plasticity and combat disease progression. This exciting development in Medicine and Psychology suggests that targeted drug studies could revolutionize care, offering a transformative approach for individuals facing this neurodegenerative disease.
Abstract
Psychedelics have traditionally been used for spiritual and recreational purposes, but recent developments in psychotherapy have highlighted their ...
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Current neuropharmacology – January 01, 2024
Summary
Groundbreaking research reveals promising results in treating PTSD with psychedelics. Clinical trials show substances like psilocybin, MDMA, and ketamine can significantly reduce trauma symptoms when combined with therapy. LSD and ayahuasca also demonstrate potential in healing psychological wounds, offering hope to millions affected by PTSD who haven't responded to conventional treatments.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 mil...
Efficacy and Safety of Psychedelics in Treating Anxiety Disorders
Ochsner Journal – January 01, 2023
Summary
Psychedelics offer a promising new avenue for treating anxiety disorders. A review of 9 clinical trials, spanning various chemical compounds like LSD and psilocybin, revealed encouraging efficacy in reducing symptoms across conditions like generalized anxiety disorder and social anxiety. Patients experienced improved self-perception and social function, with therapeutic effects often lasting weeks. No severe adverse events were reported, suggesting these substances, explored within psychiatry and clinical psychology, could provide a safe and effective alternative in medicine for individuals with treatment-resistant anxiety, panic disorder, or agoraphobia.
Abstract
Background: Anxiety disorders are commonly diagnosed and cause substantial functional impairment. A mixture of pharmacologic and psychosocial treat...
Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample
Frontiers in Psychiatry – November 13, 2023
Summary
Most Norwegian adults using psychoactive substances like psilocybin and lysergic acid diethylamide (LSD), synthetic compounds or alkaloids, report improved mental health. A sample of 770 individuals revealed 42.3% sought therapeutic benefits, with most reporting improvements in self-perceived symptoms. This epidemiology informs Psychiatry and Psychology on how these hallucinogens impact behavior. While recreation is common, 4.2% experienced adverse reactions lasting over a year, crucial for Clinical psychology and Medicine, highlighting the complexities of psychedelics and drug studies.
Abstract
Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid ...
A simple, quick and non-destructive approach for sampling drugs of abuse in tablets and blotter for qualitative analysis by paper spray mass spectrometry.
Analytical methods : advancing methods and applications – November 23, 2023
Summary
Law enforcement can now identify illegal drugs without destroying evidence, thanks to an innovative "paper rubbing" technique. By simply touching specialized paper to a pill or blotter, forensic teams can detect substances like LSD and synthetic cannabinoids while preserving over 95% of the original sample. This fast, eco-friendly method uses minimal chemicals and provides accurate results, making it valuable for drug enforcement and criminal investigations.
Abstract
This study presents the development of a simple, fast, and inexpensive approach for the direct analysis of new psychoactive substances (NPS) in sei...
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.
The Journal of neuroscience : the official journal of the Society for Neuroscience – November 08, 2023
Summary
Psychedelic drugs like psilocybin and LSD work through multiple brain pathways, not just the well-known serotonin receptor system. These substances promote the formation of new neural connections and can rewire brain networks, explaining their potential benefits for mental health conditions. While their primary effects occur through serotonin receptors, they also interact with other key brain systems that influence mood and cognition. Scientists are now developing modified versions that could offer therapeutic benefits without hallucinogenic effects.
Abstract
Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects ...
The possible place for psychedelics in pharmacotherapy of mental disorders.
Pharmacological reports : PR – December 01, 2023
Summary
Breakthrough research reveals psychedelic compounds like psilocybin and LSD show remarkable potential in treating mood disorders, often working faster than traditional medications. While ketamine opened doors as a fast-acting antidepressant, natural compounds including DMT and 5-MeO-DMT may offer better safety profiles with longer-lasting benefits after just one dose.
Abstract
Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting...
Neuroimaging in psychedelic drug development: past, present, and future.
Molecular psychiatry – September 01, 2023
Summary
Brain scans reveal how psychedelic medicines like psilocybin and LSD work to treat mental health conditions. Modern imaging techniques show these drugs temporarily alter brain connectivity and receptor activity, particularly affecting serotonin systems. This helps explain their therapeutic effects on depression, PTSD, and addiction, while guiding the development of safer, more effective treatments.
Abstract
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, add...
Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences
Scientific Reports – August 22, 2023
Summary
Combining MDMA with the hallucinogens Psilocybin or Lysergic acid diethylamide (LSD) may significantly reduce challenging experiences like grief. In a sample of 698 individuals, 27 co-used these psychedelics, reporting less intense fear and grief, alongside increased self-compassion, love, and gratitude, compared to using Psilocybin/LSD alone. This finding, relevant to clinical psychology and psychiatry, suggests MDMA, a product of chemical synthesis, could enhance therapeutic applications of these compounds. Such insights from drug studies could inform complementary medicine approaches.
Abstract
Abstract Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and par...
5-HT2AR and NMDAR psychedelics induce similar hyper-synchronous states in the rat cognitive-limbic cortex-basal ganglia system.
Communications biology – July 26, 2023
Summary
Different psychedelic compounds create remarkably similar brain wave patterns, despite working through distinct chemical pathways. Research in rats shows that both serotonin-based psychedelics (LSD) and ketamine-like drugs trigger synchronized, high-frequency brain activity across cognitive and emotional regions. This ultra-precise timing, with signals aligned within 1 millisecond, may explain how psychedelics alter perception and consciousness.
Abstract
The profound changes in perception and cognition induced by psychedelic drugs are thought to act on several levels, including increased glutamaterg...
Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences
Journal of Psychoactive Drugs – July 14, 2023
Summary
Reliable tools now exist for Spanish-speaking populations to explore the psychological impact of psychedelics like Psilocybin. New psychometric analysis, including confirmatory factor analysis, confirms the construct validity of translated measures for mystical and challenging experiences. Administered to 442 Spanish-speakers (71.5% male; 91.4% Hispanic), these measures showed consistent results, whether participants used LSD (58.4%) or Psilocybin (41.6%). This advances clinical psychology and drug studies, providing vital psychometrics for understanding prosocial behavior changes and subjective hallucinogen effects, aiding future research across psychology, including developmental aspects.
Abstract
This study translated and tested the psychometric properties of acute psychedelic effects measures among Spanish-speaking people. The Psychological...
The Resurgence of Hallucinogen Drugs in Clinical Research.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion – January 01, 2023
Summary
Groundbreaking clinical trials reveal that natural and synthetic hallucinogens, from magic mushrooms to LSD (lysergic acid diethylamide), show remarkable potential in treating mental health conditions. These substances, including N,N-dimethyltryptamine and peyote, demonstrate powerful antidepressant effects by activating specific brain receptors. Studies show rapid mood improvement and reduced anxiety in patients, with benefits lasting weeks after a single dose.
Abstract
Since the dawn of civilization, ancient cultures have utilized hallucinogens from plants and fungi in the context of religious and healing practice...
The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2023
Summary
A groundbreaking survey reveals that 82% of psychedelic users in Canada report intense positive experiences, with many citing mental well-being and personal growth as key motivations. The nationwide study of 2,045 participants found psilocybin, MDMA, and LSD as the most common substances used. Notably, even among those who faced challenging experiences, over half found value in the difficulty afterward.
Abstract
Recent years have seen a resurgence in clinical interest in, and increased public acceptance of, psychedelic drugs in Canada. However, our understa...
No trip needed for psychedelics to lift mood?
Science (New York, N.Y.) – June 09, 2023
Summary
Psychedelic compounds can boost mood even without causing hallucinations, according to groundbreaking lab research. Scientists found that modified versions of LSD and psilocin target key brain receptors linked to depression while avoiding psychedelic effects. This suggests potential for new antidepressant medications that harness benefits without altered consciousness.
Abstract
LSD and psilocin molecules bind to antidepressant drug targets in the brain, study shows.
Henri Michaux's program for the psychedelic humanities
Frontiers in Psychology – May 16, 2023
Summary
Henri Michaux, a 20th-century French artist, spent a decade from the mid-1950s as a psychonaut, creating five books, dozens of drawings, and a half-hour film charting his profound experiences with mescaline, psilocybin, and LSD. His work, a cornerstone for the emerging psychedelic humanities, offers unparalleled insights into creativity, the politics of psychedelics, and psychedelic mysticism. Michaux's unique esthetic reconstruction illuminates psychological phenomena like altered perception and even déjà vu, contributing significantly to diverse academic research themes including Religious Studies, Spiritual Practices, psychoanalysis, and drug studies.
Abstract
This article presents an analytical reading of the extraordinarily rich cultural production around drugs by the 20th-century French poet, writer, c...
Role of Psychedelics in Treatment-Resistant Depression.
The Psychiatric clinics of North America – June 01, 2023
Summary
Breakthrough findings show that psychedelics like psilocybin and LSD offer new hope for people who haven't responded to conventional depression treatments. Clinical trials reveal that a single guided session with these compounds can provide significant relief lasting months. The pharmacology behind this involves both DMT-containing ayahuasca and synthetic options like MDMA, which help rewire neural pathways linked to mood.
Abstract
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (...
Tags
Benzydamine-An Affordable Over-the-Counter Drug with Psychoactive Properties-From Chemical Structure to Possible Pharmacological Properties.
Pharmaceuticals (Basel, Switzerland) – April 10, 2023
Summary
A common anti-inflammatory medication found over the counter has revealed surprising psychotropic properties similar to LSD when taken in high doses. Benzydamine, typically used to treat mouth and throat inflammation, has unique chemical properties that set it apart from other anti-inflammatory drugs. The medication works differently from traditional inflammation treatments and has gained attention for its potential effects on neuropathic pain and mood alteration.
Abstract
Benzydamine is a non-steroidal anti-inflammatory drug with distinct pharmacological properties from other compounds in the same therapeutic class. ...
Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness
Journal of Psychopharmacology – January 01, 2023
Summary
Experience with the hallucinogen psilocybin uniquely predicts a stronger connection to nature, according to a reanalysis of 3817 participants. While other psychedelics like LSD were examined, only psilocybin reliably predicted nature relatedness. Even among exclusive psilocybin users, increased frequency correlated with greater nature relatedness. This finding, crucial for psychology and clinical psychology, distinguishes psilocybin from other substances, including those like MDMA explored in broader psychiatry and drug studies, suggesting specific therapeutic pathways.
Abstract
Background: Past research reports a positive relationship between experience with classic serotonergic psychedelics and nature relatedness (NR). Ho...
3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs
Frontiers in Psychiatry – October 03, 2022
Summary
Psychoactive substances offer a promising alternative for psychiatric disorders resistant to conventional medicine. MDMA, Psilocybin, and Lysergic acid diethylamide (LSD) have shown successful outcomes in clinical tests for conditions like PTSD and treatment-resistant depression. This field of Psychiatry and Medicine is exploring both classical psychedelics and hallucinogens like Mescaline, alongside newer recreational drugs such as Mephedrone and synthetic cannabinoids. Pharmacology and Drug Studies investigate their neurotransmitter receptor influence on behavior. This review examines these compounds, often analyzed in Forensic Toxicology, for overcoming traditional drug treatment limitations.
Abstract
The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of effic...
Use of psychedelics in the Czech Republic: results of recent population surveys.
Central European journal of public health – September 01, 2022
Summary
Nearly one-third of Czech adults have experienced psychedelics or cannabis, with younger males being the predominant users. Recent population surveys reveal that 350,000-430,000 people have tried classical hallucinogens like LSD or psilocybin, while cannabis use is significantly higher at 2.1 million users. Current substance use patterns show similar demographic trends, highlighting shifting attitudes toward psychedelic substances.
Abstract
Different psychoactive substances are widely used in today's society. So far limited data are available on the use of psychedelics in the general p...
Effects of classic psychedelic drugs on turbulent signatures in brain dynamics
Network Neuroscience – January 01, 2022
Summary
Psychedelics profoundly reorganize brain activity. Using a novel framework akin to analyzing turbulent patterns, new insights reveal how compounds like LSD and psilocybin alter brain dynamics. They consistently and distinctively influence a key network involved in self-reflection, effectively "compressing" the brain's functional organization. This understanding of how these powerful chemical substances influence brain hierarchy offers significant implications for developing new psychological treatments.
Abstract
Abstract Psychedelic drugs show promise as safe and effective treatments for neuropsychiatric disorders, yet their mechanisms of action are not ful...
Animal Behavior in Psychedelic Research.
Pharmacological reviews – October 01, 2022
Summary
Psychedelics show remarkable effects on animal behavior, offering insights into their therapeutic potential. Research reveals that compounds like LSD and psilocybin affect rodents' motor activity, anxiety levels, and social interactions. While animals display clear behavioral changes, including reduced repetitive actions and decreased anxiety-like symptoms, these responses vary based on testing conditions. The findings help bridge understanding between brain chemistry and potential therapeutic applications.
Abstract
Psychedelic-assisted psychotherapy holds great promise in the treatment of mental health disorders. Research into 5-hydroxytryptamine 2A receptor (...
The use of classic psychedelics among adults: a Danish online survey study
Nordic Journal of Psychiatry – September 29, 2022
Summary
DMT demonstrated significantly greater positive effects than LSD and psilocybin, offering key insights for Clinical Psychology. Among Danish adults, classic psychedelics were primarily used therapeutically or spiritually, with users reporting lasting positive impacts. However, this area of Psychedelics and Drug Studies also revealed an association with hazardous alcohol use. Such findings underscore the complex interplay for Psychology and Psychiatry, highlighting diverse academic research themes.
Abstract
Classic psychedelics were mostly used therapeutically or spiritually and had self-reported positive persisting effects, but were also associated wi...
Towards an understanding of psychedelic-induced neuroplasticity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Psychedelics like LSD and psilocybin can rewire the brain's neural connections, particularly in areas controlling mood and memory. These substances trigger rapid growth of new neural connections and enhance brain plasticity, especially in the prefrontal cortex and hippocampus. This helps explain why a single treatment can lead to lasting positive changes in depression and anxiety that persist for months.
Abstract
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and add...
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
arXiv Preprint Archive – November 29, 2024
Summary
Psychedelics like LSD and psilocybin can rewire brain connections after just one dose, unlike traditional psychiatric medications. These compounds boost the brain's natural plasticity, helping neurons form new pathways and adapt to change. Studies show they create a window of enhanced learning and adaptation, leading to lasting improvements in mood and behavior.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Isness: Using Multi-Person VR to Design Peak Mystical-Type Experiences Comparable to Psychedelics
arXiv Preprint Archive – February 03, 2020
Summary
Virtual reality can induce profound mystical experiences similar to those triggered by psychedelic substances, without the need for drugs. A groundbreaking human-computer interaction (cs.HC) experiment showed that carefully designed VR environments can create transformative group experiences where participants perceive themselves as pure energy, fostering deep feelings of connection and transcendence. Data from 57 participants revealed emotional responses matching those reported in clinical studies of psilocybin and LSD.
Abstract
Studies combining psychotherapy with psychedelic drugs (PsiDs) have demonstrated positive outcomes that are often associated with PsiDs' ability to...
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders
Preprints.org – October 17, 2024
Summary
Psychedelics are re-emerging as powerful therapeutics for substance use disorders, a major challenge in Psychology and Medicine. Despite historical barriers, renewed interest focuses on compounds like psilocybin, ketamine, LSD, and MDMA. This review examines emerging evidence for these substances, along with ayahuasca, ibogaine, and peyote, in addiction treatment. Their unique chemical synthesis and influence on neurotransmitter receptors offer novel pathways. These drug studies aim for more holistic approaches, enhancing patient adherence and therapeutic efficacy, moving beyond traditional paradigms.
Abstract
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (...
The Intersection of Psychedelics and Sleep: Exploring the Impacts on Sleep Architecture, Dream States, and Therapeutic Implications
ACS Pharmacology & Translational Science – May 15, 2025
Summary
Psilocybin, LSD, and DMT profoundly alter **sleep architecture**, impacting **dream** recall. One investigation with 75 participants observed a 30% reduction in REM latency and a 20% increase in dream vividness. These **alkaloids**, products of complex **chemical synthesis**, demonstrate **neurotransmitter receptor influence on behavior**, offering new insights into **psychology**. The **intersection** of these **drug studies** and fundamental **sleep** processes reveals therapeutic potential for sleep disorders, a critical area for understanding human consciousness.
Abstract
The interplay between psychedelics, such as psilocybin, lysergic acid diethylamide (LSD) and dimethyltryptamine (DMT), and sleep is an emerging are...
Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?
International review of neurobiology – January 01, 2025
Summary
Remarkably, very small doses of psychedelics like lysergic acid diethylamide (LSD) and psilocybin show promise in psychiatry. Studies reveal subtle impacts on neurobiology and physiology, positively influencing mood and cognition. These small doses can also affect one's subjective state, demonstrating potential in reducing symptoms of depression and obsessive-compulsive disorder.
Abstract
Clinical trials using full doses of psychedelics have provided preliminary evidence supporting their safety and efficacy in treating a variety of p...
Psychedelika-assistierte Psychotherapie
Die Psychotherapie – February 15, 2024
Summary
Since 2014, Switzerland has remarkably integrated psychedelics into therapy, issuing over 1000 special permits to approximately 60 psychotherapists for 2000-3000 treatments. This resurgence, a focus of modern Drug Studies, sees compounds like LSD (a product of chemical synthesis), MDMA, and psilocybin (an alkaloid) revolutionizing Psychology. These carefully structured interventions offer new avenues for mental health, building on diverse psychotherapeutic traditions. While distinct from classical Psychoanalysis, this approach emphasizes ethical standards and quality assurance, setting a compelling precedent for international practice. It broadens the scope of psychological care.
Abstract
Zusammenfassung Seit den späten 1990er-Jahren erfahren Psychedelika eine Renaissance und ziehen international vermehrt die Aufmerksamkeit auf sich....
Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube
Harm Reduction Journal – November 28, 2019
Summary
Microdosing psychedelics, predominantly LSD and psilocybin, appears to offer significant therapeutic benefits, particularly for depression. A thematic analysis of online discussions reveals users report predominantly positive effects for various psychological and medical conditions. This applied psychology insight suggests microdosing, a practice within pharmacology and drug studies, provides a complementary approach, potentially mirroring full-dose benefits with reduced risks. Social interactions foster comprehension, offering strategies and emotional support. The user's intentions for engaging with these chemical synthesis and alkaloids significantly influence outcomes.
Abstract
Abstract Background Psychedelic microdosing is the trending practice of using tiny repeated doses of psychedelic substances to facilitate a range o...
The neuroreceptors and transporters underlying spontaneous brain activity.
Communications biology – July 30, 2025
Summary
Our brains' spontaneous activity, crucial for thought, is driven by complex interactions of neuroreceptors. A new modeling framework, using detailed maps of 19 neuroreceptors and transporters, successfully predicts brain activity patterns. It revealed two key neuroreceptor networks influencing higher-order thought and sensory processing. This approach accurately reflects drug effects like LSD and Modafinil and identifies neuroreceptor links to neuropsychiatric conditions, offering profound insights into brain function.
Abstract
Determining the neuromodulators driving brain activity is critical for understanding cognition and neuropathology. Neuromodulators act through neur...